FAQ: What Role Does a New Mechanism of Action Play in Your Prescribing Decisions of IBS-C Therapy?
GHAPPcast26 Aug 2024

FAQ: What Role Does a New Mechanism of Action Play in Your Prescribing Decisions of IBS-C Therapy?

Thank you to Ardelyx for your support of this FAQ Video Module.

For years, the primary treatment options for irritable bowel syndrome with constipation (IBS-C) have been limited to secretagogues, offering varying doses and tolerability. However, a new mechanism of action (MOA) is now available, revolutionizing treatment choices for healthcare providers and patients alike. In this discussion, Kim Orleck, PA-C, from Atlanta Gastroenterology Associates, explores the triple-action MOA of this novel IBS-C therapy and how it enhances clinical decision-making.

This innovative therapy works by targeting the sodium-hydrogen exchanger isoform 3 (NHE3) on the apical surfaces of the small intestine and colon. By inhibiting NHE3, three key physiological effects occur. First, dietary sodium absorption is reduced, leading to increased luminal water content, which accelerates intestinal transit and softens stool consistency. Second, intestinal permeability is decreased, which helps to reduce abdominal pain. Lastly, visceral hypersensitivity is lowered, further alleviating the pain associated with IBS-C. These combined actions address multiple aspects of IBS-C pathophysiology, providing a minimally absorbed yet highly effective approach to symptom management.

With this exciting advancement, healthcare providers now have a novel treatment option that expands beyond traditional secretagogues, offering a new level of relief for patients struggling with IBS-C. To learn more, visit the GHAPP website for additional insights and expert perspectives on IBS-C management.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(154)

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Mai 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Mai 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Mai 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Mai 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Mai 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...

14 Apr 18min

Populært innen Helse

fastlegen
rss-gukild-johaug
lydartikler-fra-aftenposten
psykodrama
hvordan-har-du-det-mann
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
foreldreradet
rss-skravla-gar
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
rss-garne-damer
morten-ramm-lar-kakla-ga-til-du-sovner
klimaks
rss-lopedrommen
hjernesterk
g-punktet
treningsprat
rss-kull
sinnsyn
hverdagspsyken